the program demonstrated a favorable safety profile but the Phase IIb obesity trial produced modest weight-loss effects (mean reduction in treated groups roughly 2.6 kg vs
Its usually not serious, but its very contagious and can spread quickly through skin contact or respiratory transmission among people of any age, especially in schools
For milder cases, you might see subtle boosts in energy, brain fog reduction, and mood lifts within the first week or two
- when there is risk of torsades de pointes, for example in patients with prolonged QT, concomitant administration of other medications that produce torsades de pointes (amiodarone, quinidine, bepridil, IV erythromycin, halofrantine, pentamidine, sparfloxacin, sultopride, vincamine, betrilio, disopyramide, sotalol, etc)
PubMed ID: 11713213 Ng FM et al
Clinical trial data extend to 2-3 years of continuous use with no significant safety concerns emerging